Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement

Nephrology Dialysis Transplantation

Volumn 23, Issue 4, 2008, Pages 1307-1312

  Hu, Weixin ^a,b   Liu, Chunbei ^b   Xie, Honglang ^a   Chen, Huiping ^a   Liu, Zhihong ^a   Li, Leishi ^a  

^a Research Institute of Nephrology

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Antineutrophil cytoplasmic antibody; Cyclophosphamide; Mycophenolate mofetil; Vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; STEROID; CREATININE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PRODRUG;

ADULT; ANCA ASSOCIATED VASCULITIS; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; MALE; PNEUMONIA; PRIORITY JOURNAL; REMISSION; VOMITING; BIOPSY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULUS; HOSPITALIZATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOPSY; CREATININE; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PRODRUGS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VASCULITIS;

EID: 42949083859     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm780     Document Type: Article

References (28)

1. Morgan MD, Harper L, Williams et al. Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol 2006; 17: 1224-1234
2. Jayne D, Rasmussen N, Andrassy K et al. Randomized trial of cyclophosphamide versus azathioprine as remission maintenance therapy for ANCA-associated vasculitis. N Engl J Med 2003; 349:36-44
3. Little MA, Nazar L, Farrington K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity. Nephrol Dial Transplant 2004; 19: 356-364
4. Hu WX, Liu ZH, Liu CB et al. Prognosis of microscopic polyaniitis with renal involvement: report of 60 Chinese patients. Chin Med J 2005; 118: 289-292
5. Hu WX, Liu ZH, Chen HP et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002; 115: 705-709
6. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
7. Hu WX, Tang Z, Cheng Z et al. Mycophenolate mofetil for type III crescentic glomerulonephritis. Chin J Nephrol Dial Transplant 1999; 8: 323-326 (In Chinese)
8. Waiser J, Budde K, Braasch E et al. Treatment of acute c-ANCA positive vasculitis with mycophenolate mofetil. Am J Kidney Dis 1999; 34: 9
9. Nowack R, Gobel U, Klooker P et al. MMF for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-1971
10. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-283
11. Jennette JC, Falk RJ, Andrassy K. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
12. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671-678
13. Huang YF, Liu ZH, Huang HD et al. Effects of mycophenolate acid on endothelial cells. Intern Immunopharmacol 2005; 5: 1029-1039
14. Li LS, Liu ZH, Hu WX. Mycophenolate mofetil showed inhibitory effect on VCAM expression during successful treatment of diffuse proliferative lupus nephritis (SLE-DPGN) with vascular lesion. Am J Soc Nephrol 1998; 9: 153A
15. Ahsan N, Holman MJ, Katz DA et al. Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy. Clin Transplant 1997; 11: 94-97
16. Joy MS, Hogan SL, Jennette JC et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725-2732
17. Gaskin G, Jayne D, Group EVS. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis [Abstract]. J Am Soc Nephrol 2002; 13: 2A
18. Klemmer PJ, Chalermskulrat W, Reif MS et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42: 1149-1153
19. Matic G, Michelsen A, Hofmann D et al. Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment. Ther Apher 2001; 5: 68-72
20. Slot MC, JW Cohen Tervaert, Franssen CFM et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 670-677
21. Han WK, Choi HK, Roth RM et al. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003; 63: 1079-1085
22. de Groot K, Adu D, Savage CO. The value of pulse Cyclophosphamide in ANCA associated vasculitis: meta analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018-2027
23. Reinhold-Keller E et al. An interdiscripilnary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-1032
24. Hauer HA, Bajema IM, van Houwelingen HC et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int, 2002; 60: 80-89
25. Chen M, Yu F, Zhang Y et al. Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J 2005; 81: 723-727
26. Chen M, Yu F, Zhang Y et al. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int 2005; 68: 2225-2229
27. Fujimoto S, Shigehiro Uezono S, Hisanaga S et al. Incidence of ANCA-associated primary renal vasculitis in the miyazaki prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 2006; 1: 1016-1022
28. Vizjak A, Rott T, Koselj-Kajtna M et al. Histological and immunological study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis 2003; 41: 539-549